Despite the enormous importance of cisplatin as a chemotherapeutic agent, its application is impacted by dose-limiting side effects and lack of selectivity for cancer cells. Researchers can overcome these issues by taking advantage of the pro-drug nature of the platinum(IV) oxidation state, and by modifying the coordination sphere of the metal centre with specific vectors whose receptors are overexpressed in tumour cell membranes (e.g., carbohydrates). In this paper we report the synthesis of four novel carbohydrate-modified Pt(IV) pro-drugs, based on the cisplatin scaffold, and their biological activity against osteosarcoma (OS), a malignant tumour which is most common in adolescents and young adults. The carbohydrate-targeting vectors and Pt scaffold are linked using copper-catalysed azide–alkyne cycloaddition (CuAAC) chemistry, which is synonymous with mild and robust reaction conditions. The novel complexes are characterised using multinuclear 1D-2D NMR (1H, 13C and 195Pt), IR, HR-MS, Elem. Analyses, and CV. Cytotoxicity on 2D and 3D and cell morphology studies on OS cell lines, as well as non-cancerous human foetal osteoblasts (hFOBs), are discussed.
尽管
顺铂作为一种化疗药物非常重要,但其应用却受到剂量限制性副作用和对癌细胞缺乏选择性的影响。研究人员可以利用
铂(IV)氧化态的促药物性质,并通过使用肿瘤细胞膜上受体过度表达的特定载体(如
碳水化合物)来修饰
金属中心的配位层,从而克服这些问题。在本文中,我们报告了基于
顺铂支架合成的四种新型
碳水化合物修饰
铂(IV)原药及其对骨肉瘤(OS)的
生物活性。使用
铜催化
叠氮-炔环加成(Cu
AAC)
化学将
碳水化合物靶向载体和
铂支架连接起来,这种
化学反应条件温和而稳定。新型复合物的表征采用了多核 1D-2D NMR(1H、13C 和 195Pt)、IR、HR-MS、Elem.分析和 CV。还讨论了二维和三维细胞毒性,以及对操作系统
细胞系和非癌人类胎儿成骨细胞(hFOBs)的细胞形态学研究。